# CameL

Source: https://onco.cc/trials/camel/  
OnCo record `camel` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The trial that made camrelizumab a first-line lung cancer option in China, one of several domestic PD-1 antibodies to reproduce the KEYNOTE-189 result.

## Summary

412 patients, open label. Median progression-free survival 11.3 versus 8.3 months (hazard ratio 0.60); overall survival favoured camrelizumab in later follow-up. NMPA approval June 2020. Its companion CameL-sq did the same in squamous disease. Camrelizumab is notable for reactive cutaneous capillary endothelial proliferation, a side effect largely unique to it.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-10
- Tags: china
- Registry id: NCT03134872
- Phase: 3
- Setting: First-line non-squamous NSCLC without EGFR or ALK alterations, China: camrelizumab plus carboplatin and pemetrexed vs chemotherapy alone
- Sponsor: Jiangsu Hengrui Pharmaceuticals
- Enrolled: 419
- Result: PFS 11.3 vs 8.3 months, HR 0.60.
- Outcomes: Progression-free survival: Camrelizumab + chemotherapy 11.3 months vs Chemotherapy 8.3 months, HR 0.6

## Sources

- ClinicalTrials.gov NCT03134872: https://clinicaltrials.gov/study/NCT03134872
- Lancet Respir Med 2021: https://doi.org/10.1016/S2213-2600(20)30365-9

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)
- people: [Caicun Zhou](https://onco.cc/people/zhou-caicun/)
- key papers: [Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial](https://onco.cc/key-papers/paper-camel-j-thorac-oncol-2023-update/), [Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial](https://onco.cc/key-papers/paper-camel-lancet-respir-med-2021/)

---
JSON: https://onco.cc/api/v1/entities/camel.json